Comparative efficacy of various wound dressings on scar formation following thyroidectomy: a systematic review and meta-analysis.

J Comp Eff ResSep 4, 2026 (epub)
Clinical ResearchGeneral SurgeryPlastic Surgery

Yixue Jiang

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of various postoperative wound interventions on scar formation following thyroidectomy in adults. The analysis included 14 randomized controlled trials, revealing that while overall interventions did not significantly improve scar outcomes (SMD: -0.21; 95% CI: -0.45 to 0.04; p = 0.10), wound-protector devices showed a significant improvement (SMD: -0.84; p < 0.001).

Key findings

  • Overall, postoperative wound interventions did not significantly improve scar outcomes (SMD: -0.21; p = 0.10).
  • Wound-protector devices demonstrated a significant improvement in scar outcomes (SMD: -0.84; p < 0.001).
  • Tissue adhesives showed no measurable scar-quality advantage over conventional sutures (SMD: 0.14; p = 0.29).
  • Evidence for continuous diffusion oxygen therapy remains preliminary, evaluated in only one trial.

Why it matters

Understanding the comparative effectiveness of wound interventions is crucial for clinicians aiming to minimize scarring and enhance cosmetic outcomes after thyroid surgery. This knowledge can guide postoperative care strategies.

Source

PubMed · PMID 42695709

Published in J Comp Eff Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.